This is an amended filing · View original →
SLSBio(Specialty Lab Solution Bio) Co., Ltd Q3 revenue KRW 1.7 billion, loss of KRW 0.8 billion from main business
AI summary · Not investment advice
In Q3, the company sold KRW 1.7 billion worth and lost KRW 0.8 billion from its main business; sales rose 459.7% from a year earlier and 27.8% from the prior quarter.
Operating profit · 3 months
KRW -810.5 million
Key facts
- Revenue (3 months)
- KRW 1.7 billion
- Net income (3 months)
- KRW -819.1 million
- Revenue (prior-year 3 months)
- KRW 295.7 million
- Revenue (year to date)
- KRW 3.9 billion
- Operating profit (prior-year 3 months)
- KRW -1.8 billionOperating loss
- Operating profit (year to date)
- KRW -2.7 billionOperating loss
- Net income (prior-year 3 months)
- KRW -1.9 billionNet loss
- Net income (year to date)
- KRW -2.7 billionNet loss
Commentary
AI commentary · Not investment advice
What happened
SLS Bio filed its quarterly report for the third quarter of 2026 on a standalone basis. Sales for the latest 3 months were KRW 1.66 billion. Sales for the same 3 months a year earlier were KRW 295.7 million. That is up 459.7% from a year earlier and up 27.8% from the previous quarter. Cumulative sales this year are KRW 3.91 billion.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 810.5 million. A year earlier, the same 3 months showed a loss of KRW 1.80 billion. The cumulative operating loss this year is KRW 2.66 billion.
What changes for shareholders
Net income (the final profit after taxes and all other items) for the latest 3 months was a loss of KRW 819.1 million. A year earlier, the same 3 months showed a net loss of KRW 1.87 billion. The cumulative net loss this year is KRW 2.73 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
S